-
Mashup Score: 2
A recent study from researchers in Drexel University’s College of Nursing and Health Professions and Dornsife School of Public Health aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition.
Source: drexel.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Could Eating Turkey Ease Colitis? - 5 month(s) ago
Thanksgiving is often a time for thinking about your belly. For those with an inflammatory bowel diseases like ulcerative colitis, feasting can be associated with stress. New research in mice suggests that certain foods – especially those high in tryptophan, like turkey, pork, nuts and seeds – could reduce the risk of a colitis flare. The findings point to a noninvasive method of improving…
Source: www.jefferson.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors | Jefferson Health - 5 month(s) ago
Copyright © 2023 Thomas Jefferson University Hospitals. All Rights Reserved. Jefferson holds itself accountable, at every level of the organization, to nurture an environment of inclusion and respect, by valuing the uniqueness of every individual, celebrating and reflecting the rich diversity of its communities, and taking meaningful action to cultivate an environment of fairness, belonging &…
Source: www.jeffersonhealth.orgCategories: General Medicine News, Onc News and JournalsTweet-
#TrialTuesday: @KayvanZarrabi is leading a first-in-human trial evaluating the safety, efficacy, & tolerability of the PARG inhibitor IDE161 as a monotherapy in metastatic solid tumors harboring BRCA1/2 mutations or other HR defects now enrolling at SKCC: https://t.co/0RatzX3BpL https://t.co/Eg0fWl27bq
-
-
Mashup Score: 4Paper: Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas Hematology Disease Topics & Pathways: Research, clinical trials, adult, Lymphomas, Clinical Research, T Cell lymphoma, drug development, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human Martine Bagot, MD, PhD 1 *, Youn H. Kim, MD 2, Larisa J. Geskin, MD 3 *, Pablo L. Ortiz-Romero, MD, PhD 4 *, Ellen Kim, MD 5
Source: ash.confex.comCategories: General Medicine News, Onc News and JournalsTweet-
Dr. Pierluigi Porcu will present promising data from the TELLOMAK trial of the novel agent lacutamab in the cohort of patients with Sézary syndrome, an aggressive type of cutaneous T-cell lymphoma, during an oral presentation today at #ASH23 at 3 pm PT ➡️ https://t.co/BWDLYmuAsY https://t.co/w12pY2mOZc
-
-
Mashup Score: 5
Lindsay Wilde, MD, Sidney Kimmel Cancer Center, Jefferson Health and Andrew H. Wei, MBBS, PhD, Peter MacCallum Cancer Centre and Royal Melbourne Hospital Wilde: Gilead: Research Funding; Protagonist: Research Funding. This session includes novel therapies that have potential to change practice, 2 studies with selinexor (one in peds), 2 menin inhibitor studies, 1 anti-CD47 and 1 anti
Source: ash.confex.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Date: 12/14/2023 Time: 11:00AM – 6:00PM Location: Jefferson Alumni Hall Atrium For further information, please email Meredith LeBeau Meredith.LeBeau@jefferson.edu. Maintained by the Informatics Shared Resources of the Sidney Kimmel Cancer Center at Jefferson Copyright © Thomas Jefferson University. All Rights Reserved. The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to
Source: ewebapp01pa.jefferson.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy - 5 month(s) ago
PURPOSE Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of the pancreas (H) have different prognostic implications than tumors arising from the body and tail (BT). This is thought to be largely due to anatomic differences, as molecular underpinnings of survival have not been fully explored. We hypothesized that differences in the primary site of H and BT tumors might account for differential molecular outcomes and response to chemotherapy. METHODS Retrospective data from a single high-volume academic center were analyzed for hypothesis generation. A large-scale, real-world retrospective cohort of 2015 patients with next-generation sequencing (NGS) results were analyzed from a Real-World Evidence database. Progression-free survival (PFS) was evaluated from the initiation of first line of therapy for advanced disease until discontinuation because of progression. HR and P values were computed via Cox regre
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Study shows importance of platinum-based therapy in body/tail PDAC tumors, which are more commonly found to have DDR pathway alterations than tumors arising from head of the pancreas @JCOPO_ASCO: https://t.co/fBqq6D5kE0 #PancreaticCancerAwareness 💜 #ResearchWednesday @idamicaily https://t.co/w9HZW5qgYs
-
-
Mashup Score: 6
S1914, A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC. This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune…
Source: www.jeffersonhealth.orgCategories: General Medicine News, Onc News and JournalsTweet-
#TrialTuesday: Dr. Maria Werner-Wasik is leading a trial studying whether adding the immunotherapy drug atezolizumab to the usual radiation therapy works better in treating patients with early-stage non-small cell lung cancer. https://t.co/QSMiioFylg #LungCancerAwareness #RadOnc https://t.co/qpyxj0pvLl
-
-
Mashup Score: 1Support the Sidney Kimmel Cancer Center - 5 month(s) ago
With a gift to Jefferson, you can support path-breaking work that could one day lead to better detection, prevention, and treatment strategies for cancers of all types. You can help improve lives, giving more patients the strength to fight today and the hope for a cure tomorrow.
Source: giving.jefferson.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Support the Sidney Kimmel Cancer Center - 5 month(s) ago
With a gift to Jefferson, you can support path-breaking work that could one day lead to better detection, prevention, and treatment strategies for cancers of all types. You can help improve lives, giving more patients the strength to fight today and the hope for a cure tomorrow.
Source: giving.jefferson.eduCategories: General Medicine News, Onc News and JournalsTweet
#ResearchWednesday: A study from @drexelpubhealth professor & SKCC member Dr. Ann Klassen & colleagues highlighted barriers to maintaining a healthy diet for GI cancer patients & their caregivers, which was published in Cancer Control @SageJournals ➡️ https://t.co/bRmdrVMn7Z